Reino Heikkilä

  • Head of section
  • +47 22 93 54 27
 

Author network for Reino Heikkilä by COREMINE medical


Publications 2018

Oltedal S, Kørner H, Aasprong OG, Hussain I, Tjensvoll K, Smaaland R, Søreide JA, Søreide K, Lothe RA, Heikkilä R, Gilje B, Nordgård O (2018)
The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer
Transl Oncol, 11 (2), 436-443
DOI 10.1016/j.tranon.2018.01.015, PubMed 29475140

Oltedal S, Skaland I, Maple-Grødem J, Tjensvoll K, Janssen EAM, Gilje B, Smaaland R, Heikkilä R, Nordgård O (2018)
Expression profiling and intracellular localization studies of the novel Proline-, Histidine-, and Glycine-rich protein 1 suggest an essential role in gastro-intestinal epithelium and a potential clinical application in colorectal cancer diagnostics
BMC Gastroenterol, 18 (1), 26
DOI 10.1186/s12876-018-0752-8, PubMed 29415677

Publications 2017

Heikkilä R, Kaasa S (2017)
Chemotherapy in end-of-life care
Ann Oncol, 28 (4), 684-685
DOI 10.1093/annonc/mdx039, PubMed 28327919

Publications 2012

Nordgård O, Oltedal S, Aasprong OG, Søreide JA, Søreide K, Tjensvoll K, Gilje B, Heikkilä R, Guriby M, Lothe RA, Smaaland R, Kørner H (2012)
Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients
Ann Surg Oncol, 19 (12), 3719-26
DOI 10.1245/s10434-012-2454-8, PubMed 22752373

Publications 2011

Oltedal S, Aasprong OG, Møller JH, Kørner H, Gilje B, Tjensvoll K, Birkemeyer EM, Heikkilä R, Smaaland R, Nordgård O (2011)
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
Int J Colorectal Dis, 26 (10), 1271-7
DOI 10.1007/s00384-011-1233-5, PubMed 21573767

Publications 2010

Oltedal S, Gilje B, Kørner H, Aasprong OG, Tjensvoll K, Heikkilä R, Smaaland R, Nordgård O (2010)
Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR
Ann Surg, 251 (6), 1087-91
DOI 10.1097/SLA.0b013e3181dae1bc, PubMed 20485143

Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkilä R, Kvaløy JT, Gilje B, Smaaland R, Nordgård O (2010)
Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients
Clin Breast Cancer, 10 (5), 378-84
DOI 10.3816/CBC.2010.n.050, PubMed 20920982

Publications 2009

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR
Int J Colorectal Dis, 24 (3), 261-8
DOI 10.1007/s00384-008-0613-y, PubMed 19119477

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach
Ann Surg, 249 (4), 602-7
DOI 10.1097/SLA.0b013e31819ec923, PubMed 19300229

Publications 2008

Gilje B, Heikkilä R, Oltedal S, Tjensvoll K, Nordgård O (2008)
High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations
J Mol Diagn, 10 (4), 325-31
DOI 10.2353/jmoldx.2008.070183, PubMed 18556764

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A (2008)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann Oncol, 19 (5), 909-14
DOI 10.1093/annonc/mdm588, PubMed 18209013

Tjensvoll K, Gilje B, Oltedal S, Shammas VF, Kvaløy JT, Heikkilä R, Nordgård O (2008)
A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow
Breast Cancer Res Treat, 116 (2), 329-38
DOI 10.1007/s10549-008-0204-1, PubMed 18846421

Publications 2007

Farmen RK, Nordgård O, Gilje B, Shammas FV, Kvaløy JT, Oltedal S, Heikkilä R (2007)
Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients
Breast Cancer Res Treat, 108 (2), 251-8
DOI 10.1007/s10549-007-9592-x, PubMed 17492378

Page visits: 418